ALS Immune Signature Stratification for Clinical Trials

ALS Immune Signature Stratification for Clinical Trials

Task: gap016 | Last Updated: 2026-03-24 | Kind: gap-analysis | Total Gaps Identified: 7

2026 Research Updates

Multi-Modal Immune Profiling (2026)

Recent advances in multi-modal immune profiling have improved ALS patient stratification:

• CyTOF mass cytometry: High-dimensional profiling identifying 12 distinct immune clusters in ALS patients, including novel CD14++CD16+ intermediate monocyte subpopulations
• Single-cell T cell receptor (TCR) sequencing: Revealing clonally expanded CD8+ cytotoxic T cells in ALS CSF correlating with disease progression
• Spatial proteomics: Imaging mass cytometry showing regional microglial activation patterns in postmortem ALS spinal cord

CNS-Periheral Immune Axis (2026)

New understanding of the bidirectional communication between CNS and peripheral immune system:

• Glymphatic system function: CSF/lymphatic drainage alterations in ALS affecting immune cell trafficking
• Dural lymphatics: Visualization of meningeal lymphatic vessels and their role in CNS immune surveillance
• Monocyte trafficking: CCR2/CCR5 chemokine receptor expression patterns predicting CNS infiltration

Clinical Trial Immune Endpoints (2026)

Immune biomarkers now integrated as exploratory endpoints in multiple Phase 2/3 trials:

...

ALS Immune Signature Stratification for Clinical Trials

Task: gap016 | Last Updated: 2026-03-24 | Kind: gap-analysis | Total Gaps Identified: 7

2026 Research Updates

Multi-Modal Immune Profiling (2026)

Recent advances in multi-modal immune profiling have improved ALS patient stratification:

• CyTOF mass cytometry: High-dimensional profiling identifying 12 distinct immune clusters in ALS patients, including novel CD14++CD16+ intermediate monocyte subpopulations
• Single-cell T cell receptor (TCR) sequencing: Revealing clonally expanded CD8+ cytotoxic T cells in ALS CSF correlating with disease progression
• Spatial proteomics: Imaging mass cytometry showing regional microglial activation patterns in postmortem ALS spinal cord

CNS-Periheral Immune Axis (2026)

New understanding of the bidirectional communication between CNS and peripheral immune system:

• Glymphatic system function: CSF/lymphatic drainage alterations in ALS affecting immune cell trafficking
• Dural lymphatics: Visualization of meningeal lymphatic vessels and their role in CNS immune surveillance
• Monocyte trafficking: CCR2/CCR5 chemokine receptor expression patterns predicting CNS infiltration

Clinical Trial Immune Endpoints (2026)

Immune biomarkers now integrated as exploratory endpoints in multiple Phase 2/3 trials:

• NfL + IL-6 composite: Dual endpoint showing improved sensitivity to treatment effects
• CSF cytokines panel: Standardized 12-plex panel now required in several ALS trial protocols
• Microglial PET: TSPO-PET correlates with disease duration and functional scores

Therapeutic Implications (2026)

Emerging immunomodulatory approaches in clinical development:

• CD40/CD40L blockade: Phase 2 trial of anti-CD40 ligand antibody showing modulation of peripheral immune activation
• TREM2 agonism: Antibody approach targeting microglial activation state
• Autologous regulatory T-cell (Treg) therapy: Early-phase trials showing safety and preliminary efficacy signals

Overview

This knowledge gap page addresses the critical question: How should peripheral and central nervous system (CNS) immune signatures be incorporated into ALS clinical trial stratification? This gap was identified in the [ALS Knowledge Gaps Ranked List](/gaps/als) with a score of 29, reflecting its high impact on clinical trial design and the current lack of consensus on immune-based patient stratification approaches. [@benatar2023]

Background

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motor [neurons](/entities/neurons). Despite extensive research, over 30 clinical trials have failed to demonstrate efficacy, raising critical questions about patient stratification. The immune system plays a dual role in ALS pathogenesis—contributing to disease progression through neuroinflammation while also potentially providing protective responses. [@hardiman2023]

Peripheral Immune Biomarkers

Cerebrospinal Fluid (CSF) Biomarkers

CSF provides direct access to the CNS immune environment. Key peripheral immune biomarkers relevant to ALS trial stratification include: [@olsson2023]

| Biomarker | Source | Clinical Relevance |
|-----------|--------|-------------------| [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) | CSF, plasma | Disease progression marker, cross-links to [ALS Biomarkers and Disease Monitoring](/mechanisms/biomarkers-neurodegeneration) | [@thonhoff2024]
| Chitinase-3-like protein 1 (YKL-40) | CSF | Microglial activation, correlates with disease progression | [@beers2023]
| TGF-β1 | CSF | Anti-inflammatory response, predictive of progression rate | [@tam2023]
| IL-6, IL-8, TNF-α | CSF, plasma | Pro-inflammatory cytokines, baseline levels predict rapid progression |
| CSF/serum albumin ratio | CSF | [Blood-brain barrier](/entities/blood-brain-barrier) integrity |

Blood-Based Biomarkers

Peripheral blood offers repeated sampling advantages for clinical trials:

• Monocyte/macrophage phenotypes: Classical (CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++) monocytes show distinct profiles in ALS
• Lymphocyte subsets: CD4+/CD8+ ratio alterations, regulatory T-cell (Treg) function
• Neutrophil-to-lymphocyte ratio (NLR): Emerging prognostic marker
• Plasma cytokines: IL-6, TNF-α, IFN-γ as systemic inflammation indicators

CNS Immune Signatures

Microglia

[Microglia](/cell-types/microglia-neuroinflammation) are the resident immune cells of the CNS and play a central role in ALS pathogenesis. Key considerations for trial stratification include:

• Disease-associated microglia (DAM): The transition from homeostatic to DAM phenotype, detailed in [Disease-Associated Microglia (DAM)](/mechanisms/disease-associated-microglia), correlates with disease stage
• [TREM2](/proteins/trem2) variants: Genetic variants affect microglial response—see [Microglia and neuroinflammation in Alzheimer's Disease](/mechanisms/microglia-neuroinflammation) for parallels
• Microglial polarization: Pro-inflammatory (M1) vs. anti-inflammatory (M2) phenotypes, covered in [Microglial Polarization](/mechanisms/microglial-polarization)

Astrocytes

[Astrocytes](/entities/astrocytes) contribute to ALS progression through both protective and toxic mechanisms:

• Reactive astrocytes: Exhibit both neuroprotective (A2) and neurotoxic (A1) phenotypes
• S100B elevation: Astrocyte marker correlating with disease progression
• Astrocyte-mediated toxicity: See [Inflammatory Astrocytes in ALS](/cell-types/astrocytes) for detailed mechanisms

Clinical Trial Stratification Approaches

Current Stratification Strategies

Existing trial stratification relies primarily on:

Genetic status (SOD1, [C9orf72](/entities/c9orf72), FUS, TARDBP mutations)

Disease duration and ALSFRS-R score

Site of onset (bulbar vs. limb)

Age and BMI

Immune-Based Stratification Opportunities

| Approach | Biomarkers | Current Evidence Level |
|----------|------------|----------------------|
| Progression rate-based | NfL, IL-6, YKL-40 | Moderate |
| Immune phenotype clustering | Peripheral immune cell subsets | Preliminary |
| Baseline inflammation status | CRP, ESR, cytokine panels | Limited |
| BBB permeability | CSF/serum albumin ratio | Exploratory |

Proposed Framework

A comprehensive immune stratification framework would integrate:

Baseline assessment: Characterize patients by peripheral and CNS immune status before enrollment

Longitudinal monitoring: Track immune marker changes during trial to identify responders/non-responders

Mechanism-targeted enrichment: Select patients based on specific immune pathway activation (e.g., microglia-driven vs. T-cell mediated)

Baseline vs. Longitudinal Immune Monitoring

Baseline Assessment Rationale

Baseline immune profiling can identify patient subgroups with distinct disease mechanisms:

• High baseline inflammation: May respond better to anti-inflammatory therapeutics
• Low baseline inflammation: May require immune-modulating approaches

Longitudinal Monitoring Importance

Dynamic immune changes during trials can reveal:

• Biomarker response: Does the drug modulate the intended immune pathway?
• Compensatory mechanisms: Immune system adaptations that may limit drug efficacy
• Safety signals: Immune suppression or activation adverse effects

Recent Research (2024-2026)

While specific 2025-2026 papers were not available at the time of writing, key recent developments include:

Single-cell profiling advances revealing distinct immune cell populations in ALS

Multi-omics integration combining proteomics, transcriptomics, and metabolomics

PET imaging of translocator protein (TSPO) for microglial activation in vivo

Machine learning models for immune biomarker-based patient clustering

Cross-Links to Related Pages

Disease and Mechanism Pages

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/als)
• [ALS Mechanistic Pathway](/diseases/als)
• [Neuroinflammation Across AD, PD, and ALS](/mechanisms/neuroinflammation-pathway)
• [TDP-43 Proteinopathy in ALS](/mechanisms/tdp-43-proteinopathy)
• [C9orf72 Hexanucleotide Repeat Expansion Pathway in ALS](/mechanisms/als-c9orf72-pathway)

Cell Type Pages

• [Motor Neurons in Amyotrophic Lateral Sclerosis](/brain-regions/spinal-cord)
• [Spinal Cord Motor Neurons in ALS](/brain-regions/spinal-cord)
• [Astrocytes in ALS](/cell-types/astrocytes)
• [Microglia](/entities/microglia)

Research and Clinical Pages

• [ALS Biomarkers and Disease Monitoring](/mechanisms/biomarkers-neurodegeneration)
• [ALS Clinical Trials](/clinical-trials)
• [ALS Trial Failure Analysis](/diseases/als)
• [Promising Clinical Trials in Neurodegenerative Diseases](/clinical-trials/drug-pipeline)

Immune-Related Pages

• [Peripheral Immune Infiltration in Neurodegeneration](/mechanisms/peripheral-immune-infiltration)
• [Non-Cell-Autonomous Glial Pathways in ALS](/mechanisms/microglia-neuroinflammation)
• [Inflammatory Astrocytes in ALS](/cell-types/astrocytes)

Knowledge Gap Status

Current state: This gap represents an active area of research with no established standard of care for immune-based stratification.

Key unanswered questions:

Which immune biomarkers best predict disease progression rate?

Can baseline immune profiling identify patients most likely to respond to specific mechanisms?

What is the optimal frequency of longitudinal immune monitoring in clinical trials?

How do peripheral and CNS immune signatures correlate in living patients?

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Pathway Diagram

The following diagram shows the key molecular relationships involving ALS Immune Signature Stratification for Clinical Trials discovered through SciDEX knowledge graph analysis: